Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.

Guru Sonpavde, Gregory R. Pond, Stephanie Mullane, Ana A. Ramirez, Nicholas J. Vogelzang, Andrea Necchi, Thomas Powles, Joaquim Bellmunt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of
Original languageUndefined/Unknown
Pages (from-to)579-584
Number of pages6
JournalBJU International
Volume119
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Keywords

  • outcomes, PD-1 inhibitors, PD-L1 inhibitors, post-progression therapy, Urothelial carcinoma

Cite this

Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. / Sonpavde, Guru; Pond, Gregory R.; Mullane, Stephanie; Ramirez, Ana A.; Vogelzang, Nicholas J.; Necchi, Andrea; Powles, Thomas; Bellmunt, Joaquim.

In: BJU International, Vol. 119, No. 4, 01.04.2017, p. 579-584.

Research output: Contribution to journalArticle

Sonpavde, Guru ; Pond, Gregory R. ; Mullane, Stephanie ; Ramirez, Ana A. ; Vogelzang, Nicholas J. ; Necchi, Andrea ; Powles, Thomas ; Bellmunt, Joaquim. / Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. In: BJU International. 2017 ; Vol. 119, No. 4. pp. 579-584.
@article{b79b567d96484ac5a796a554ee06a525,
title = "Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.",
abstract = "OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of",
keywords = "outcomes, PD-1 inhibitors, PD-L1 inhibitors, post-progression therapy, Urothelial carcinoma",
author = "Guru Sonpavde and Pond, {Gregory R.} and Stephanie Mullane and Ramirez, {Ana A.} and Vogelzang, {Nicholas J.} and Andrea Necchi and Thomas Powles and Joaquim Bellmunt",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/bju.13674",
language = "Non definita",
volume = "119",
pages = "579--584",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.

AU - Sonpavde, Guru

AU - Pond, Gregory R.

AU - Mullane, Stephanie

AU - Ramirez, Ana A.

AU - Vogelzang, Nicholas J.

AU - Necchi, Andrea

AU - Powles, Thomas

AU - Bellmunt, Joaquim

PY - 2017/4/1

Y1 - 2017/4/1

N2 - OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of

AB - OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of

KW - outcomes, PD-1 inhibitors, PD-L1 inhibitors, post-progression therapy, Urothelial carcinoma

U2 - 10.1111/bju.13674

DO - 10.1111/bju.13674

M3 - Articolo

VL - 119

SP - 579

EP - 584

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 4

ER -